Investors



  • FOR INFORMATION ON
    REPORTING CHANGES AND
    REVISED REVENUE GUIDANCE click here.


  • FOR GIVEN IMAGING
    ACQUISITION INFORMATION, click here.


  • FOR 2013 INVESTOR DAY MATERIALS,
    click here.


  • For Pharmaceuticals
    spin-off information,
    click here.


  • For tax basis information
    due to the Mallinckrodt spin,
    click here.


News Release

Printer Friendly Version View printer-friendly version
<< Back
Covidien Announces the Launch of Three New Platforms for its Puritan Bennett(TM) 840 Ventilators
Puritan Bennett(TM) 840 Neonatal, Universal and Pediatric-Adult Ventilators Deliver Comprehensive Ventilation to a Broad Range of Patients

BOULDER, Colo., Dec 09, 2010 (BUSINESS WIRE) -- Covidien (NYSE: COV), a leading global provider of healthcare products and recognized innovator in mechanical ventilation and respiratory care devices, today announced that three new platforms for its Puritan Bennett(TM) 840 ventilator -- the Puritan Bennett 840 Neonatal ventilator, the Puritan Bennett 840 Universal ventilator and the Puritan Bennett 840 Pediatric-Adult ventilator -- are now available in the United States.

"Expanding on the Puritan Bennett 840 ventilator, the three new acute care ventilator platforms help clinicians safely deliver, manage and monitor ventilation for a broad range of patients," said Roger Mecca, MD, Vice President and Medical Director, Respiratory and Monitoring Solutions, Covidien. "With intuitive user interfaces and a comprehensive feature set, the Puritan Bennett 840 ventilator technology is designed to comfortably provide patients with highly responsive, flexible ventilatory support."

The Puritan Bennett 840 Neonatalventilator helps clinicians safely deliver, manage and monitor a ventilation regimen tailored for even the smallest and most critically ill neonatal patients. It offers the ability to set a tidal volume as small as 2 mL for neonates weighing as little as 300 grams without having to change to another ventilator.

The Puritan Bennett 840 Universalventilator for every patient type, from neonatal to adult, includes a neonatal CPAP mode that enables clinicians to flexibly deploy noninvasive ventilation in neonates. It supports patient-ventilator synchrony, which has been shown to facilitate spontaneous breathing. The ventilator includes features that effectively match the patient's respiratory demand and adapt to changes in patient condition.

The Puritan Bennett 840 Pediatric-Adult ventilator for pediatric to adult patients helps clinicians provide improved levels of ventilatory support by offering multiple therapies of ventilation, including invasive and noninvasive methods, as well as more advanced modes of ventilation.1, 2

"The three new Puritan Bennett 840 Ventilator platforms, for neonates, pediatric-adult and the universal technology, provide clinicians with more flexible ventilation options than ever before," said James E. Willett, Vice President and General Manager, Respiratory and Monitoring Solutions, Covidien. "We are committed to answering the needs of patients and clinicians in today's complex healthcare environment through advanced technologies and innovations."

References

1. Xirouchaki N, Kondili E, Vaporidi K, et al. Proportional assist ventilation with load-adjustable gain factors in critically ill patients: comparison with pressure support. Intensive Care Med. 2008; 34(11):2026-2034.

2. Alotaibi G, Kacmarek R, Scanlan C. Comparison of dual mode ventilation among selected adult critical care ventilators using a programmable lung simulator. Respir Care. 2004. [Abstract]

About Covidien

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2010 revenue of $10.4 billion, Covidien has approximately 42,000 employees worldwide in more than 60 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.

Photos/Multimedia Gallery Available: www.businesswire.com/cgi-bin/mmg.cgi?eid=6541074&lang=en

SOURCE: Covidien

Covidien
Sherri Hughes-Smith, 303-581-6849
Manager, Public Relations
Respiratory and Monitoring Solutions
sherri.hughes-smith@covidien.com
or
Bruce Farmer, 508-452-4372
Vice President
Public Relations
bruce.farmer@covidien.com
or
Coleman Lannum, CFA, 508-452-4343
Vice President
Investor Relations
cole.lannum@covidien.com